U.S. Food and Drug Administration Approves First LAG-3-Blocking Antibody Combination, Opdualag™ (nivolumab and relatlimab-rmbw), as Treatment for Patients with Unresectable or Metastatic Melanoma

On March 18, 2022

Notice: ob_end_flush(): failed to send buffer of zlib output compression (0) in /home/biznews/public_html/wp-includes/functions.php on line 5221

Related Post

Boeing Delivers First P-8A Poseidon to New Zealand

CarMax Announces Third Quarter Conference Call

Textron Elects Thomas A. Kennedy to Board of Directors